Teva Pharmaceuticals U

19 total trials 19 completed

Trial Pipeline

COMPLETED Phase 3

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT04976192

COMPLETED Phase 1

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

NCT01340625

COMPLETED Phase 1

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

NCT00974012

COMPLETED Phase 1

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207

COMPLETED Phase 1

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

NCT01260922

COMPLETED Phase 1

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024

COMPLETED Phase 1

Valacyclovir 1000 mg Tablet Under Fasting Conditions

NCT01149499

COMPLETED Phase 1

Cefadroxil 500 mg Capsules Under Fasting Conditions

NCT00834275

COMPLETED Phase 1

Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.

NCT00835081

COMPLETED Phase 1

Lansoprazole 30 mg DR Capsule Fasting Study

NCT01045967

COMPLETED Phase 1

Cefprozil for Oral Suspension 250 mg/5 mL, Fasting

NCT00835614

COMPLETED Phase 1

Cilostazol 50 mg Tablets Under Fasting Conditions

NCT00839930

COMPLETED Phase 1

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

NCT00838630

COMPLETED Phase 1

Azithromycin 600 Mg Tablets, Fasting

NCT00834756

COMPLETED Phase 1

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411

COMPLETED Phase 1

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

NCT00840216

COMPLETED Phase 1

Azithromycin 600 Mg Tablets, Fed

NCT00834132

COMPLETED Phase 1

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

NCT00835276

COMPLETED Phase 1

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

NCT00833664

Phase Distribution

PhaseTrial count
Phase 1 18
Phase 3 1

Therapeutic Areas

What the Pipeline for Teva Pharmaceuticals U Shows

According to the ClinicalTrials.gov registry, Teva Pharmaceuticals U is linked to 19 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 19 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Teva Pharmaceuticals U reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 18 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Teva Pharmaceuticals U is Healthy with 17 linked trials, and 2 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial